Seattle Genetics is the brainchild of Dr. Clay Siegall. With an undergraduate degree in Zoology and a doctorate in Genetics, as well as holding over 15 patents and authoring more than 70 publications, Siegall is well-suited to be the President, CEO and Chairman of the Board of Seattle Genetics.
Siegall has extensive experience in genetics. Previous positions include (from 1991-1997) the Bristol-Myers Squibb Pharmaceutical Research Institute. Also Siegall was at the National Cancer Institute, National Institutes of Health (from 1998-1991). Currently, Siegall is a member of the Board at Alder BioPharmaceuticals and the Board at Mirna Therapeutics, two biotechnology companies in the private sector.
Siegall is overseeing a variety of both clinical and preclinical products being developed. As a strong leader in research, Seattle Genetics has a cancer and autoimmune focus for work on antibody technologies. Since its public offering in 2001, Seattle Genetics has secured over $330 million in financing. There is both national and international interest in collaboration and a recent agreement with
Genentech will allow SGN-40 to have a value of $860 million. Additional partnerships with MedImmune, CuraGen, Progenics and Bayer will have generated over $65 million in the last fifteen years.
Seattle Genetics is at the forefront of cancer research. Siegall has solid years of multiple successes and his strong reputation in the field and his many achievements in pharmaceuticals will help in advancing many cancer-fighting products. Seattle Genetics is perfectly poised to continue making an impact with their products and Siegall is well-prepared to lead and celebrate innovation in the months and years to come.